BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 32048105)

  • 1. Missense PALB2 germline variant disrupts nuclear localization of PALB2 in a patient with breast cancer.
    Toh MR; Low CE; Chong ST; Chan SH; Ishak NDB; Courtney E; Kolinjivadi AM; Rodrigue A; Masson JY; Ngeow J
    Fam Cancer; 2020 Apr; 19(2):123-131. PubMed ID: 32048105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional characterization of 84 PALB2 variants of uncertain significance.
    Wiltshire T; Ducy M; Foo TK; Hu C; Lee KY; Belur Nagaraj A; Rodrigue A; Gomes TT; Simard J; Monteiro ANA; Xia B; Carvalho MA; Masson JY; Couch FJ
    Genet Med; 2020 Mar; 22(3):622-632. PubMed ID: 31636395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breast cancer-associated missense mutants of the PALB2 WD40 domain, which directly binds RAD51C, RAD51 and BRCA2, disrupt DNA repair.
    Park JY; Singh TR; Nassar N; Zhang F; Freund M; Hanenberg H; Meetei AR; Andreassen PR
    Oncogene; 2014 Oct; 33(40):4803-12. PubMed ID: 24141787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A global functional analysis of missense mutations reveals two major hotspots in the PALB2 tumor suppressor.
    Rodrigue A; Margaillan G; Torres Gomes T; Coulombe Y; Montalban G; da Costa E Silva Carvalho S; Milano L; Ducy M; De-Gregoriis G; Dellaire G; Araújo da Silva W; Monteiro AN; Carvalho MA; Simard J; Masson JY
    Nucleic Acids Res; 2019 Nov; 47(20):10662-10677. PubMed ID: 31586400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional analysis of genetic variants in the high-risk breast cancer susceptibility gene PALB2.
    Boonen RACM; Rodrigue A; Stoepker C; Wiegant WW; Vroling B; Sharma M; Rother MB; Celosse N; Vreeswijk MPG; Couch F; Simard J; Devilee P; Masson JY; van Attikum H
    Nat Commun; 2019 Nov; 10(1):5296. PubMed ID: 31757951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Validated Functional Analysis of Partner and Localizer of BRCA2 Missense Variants for Use in Clinical Variant Interpretation.
    Brnich SE; Arteaga EC; Wang Y; Tan X; Berg JS
    J Mol Diagn; 2021 Jul; 23(7):847-864. PubMed ID: 33964450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alternative transcript imbalance underlying breast cancer susceptibility in a family carrying PALB2 c.3201+5G>T.
    Duran-Lozano L; Montalban G; Bonache S; Moles-Fernández A; Tenés A; Castroviejo-Bermejo M; Carrasco E; López-Fernández A; Torres-Esquius S; Gadea N; Stjepanovic N; Balmaña J; Gutiérrez-Enríquez S; Diez O
    Breast Cancer Res Treat; 2019 Apr; 174(2):543-550. PubMed ID: 30552643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RNF168-mediated localization of BARD1 recruits the BRCA1-PALB2 complex to DNA damage.
    Krais JJ; Wang Y; Patel P; Basu J; Bernhardy AJ; Johnson N
    Nat Commun; 2021 Aug; 12(1):5016. PubMed ID: 34408138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The p.Ser64Leu and p.Pro104Leu missense variants of PALB2 identified in familial pancreatic cancer patients compromise the DNA damage response.
    Zhang Y; Park JY; Zhang F; Olson SH; Orlow I; Li Y; Kurtz RC; Ladanyi M; Chen J; Toland AE; Zhang L; Andreassen PR
    Hum Mutat; 2021 Feb; 42(2):150-163. PubMed ID: 33169439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer-causing mutations in the tumor suppressor PALB2 reveal a novel cancer mechanism using a hidden nuclear export signal in the WD40 repeat motif.
    Pauty J; Couturier AM; Rodrigue A; Caron MC; Coulombe Y; Dellaire G; Masson JY
    Nucleic Acids Res; 2017 Mar; 45(5):2644-2657. PubMed ID: 28158555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Compromised BRCA1-PALB2 interaction is associated with breast cancer risk.
    Foo TK; Tischkowitz M; Simhadri S; Boshari T; Zayed N; Burke KA; Berman SH; Blecua P; Riaz N; Huo Y; Ding YC; Neuhausen SL; Weigelt B; Reis-Filho JS; Foulkes WD; Xia B
    Oncogene; 2017 Jul; 36(29):4161-4170. PubMed ID: 28319063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutation status of RAD51C, PALB2 and BRIP1 in 100 Japanese familial breast cancer cases without BRCA1 and BRCA2 mutations.
    Sato K; Koyasu M; Nomura S; Sato Y; Kita M; Ashihara Y; Adachi Y; Ohno S; Iwase T; Kitagawa D; Nakashima E; Yoshida R; Miki Y; Arai M
    Cancer Sci; 2017 Nov; 108(11):2287-2294. PubMed ID: 28796317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequency of pathogenic germline mutation in CHEK2, PALB2, MRE11, and RAD50 in patients at high risk for hereditary breast cancer.
    Kim H; Cho DY; Choi DH; Oh M; Shin I; Park W; Huh SJ; Nam SJ; Lee JE; Kim SW
    Breast Cancer Res Treat; 2017 Jan; 161(1):95-102. PubMed ID: 27783279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Germline mutations of PALB2 gene in a sequential series of Chinese patients with breast cancer.
    Zhang K; Zhou J; Zhu X; Luo M; Xu C; Yu J; Deng M; Zheng S; Chen Y
    Breast Cancer Res Treat; 2017 Dec; 166(3):865-873. PubMed ID: 28825143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A germline
    Zhong Y; Schubert J; Wu J; Xu F; Lin F; Cao K; Zelley K; Luo M; Foster JB; Cole KA; MacFarland SP; Resnick AC; Storm PB; Li MM
    Cold Spring Harb Mol Case Stud; 2020 Aug; 6(4):. PubMed ID: 32554798
    [No Abstract]   [Full Text] [Related]  

  • 16. Splicing predictions, minigene analyses, and ACMG-AMP clinical classification of 42 germline PALB2 splice-site variants.
    Valenzuela-Palomo A; Bueno-Martínez E; Sanoguera-Miralles L; Lorca V; Fraile-Bethencourt E; Esteban-Sánchez A; Gómez-Barrero S; Carvalho S; Allen J; García-Álvarez A; Pérez-Segura P; Dorling L; Easton DF; Devilee P; Vreeswijk MP; de la Hoya M; Velasco EA
    J Pathol; 2022 Mar; 256(3):321-334. PubMed ID: 34846068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of PALB2 Germline Mutations in Early-onset and Familial Breast/Ovarian Cancer Patients from Pakistan.
    Rashid MU; Khan FA; Muhammad N; Loya A; Hamann U
    Cancer Res Treat; 2019 Jul; 51(3):992-1000. PubMed ID: 30309218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PALB2 Variants: Protein Domains and Cancer Susceptibility.
    Nepomuceno TC; Carvalho MA; Rodrigue A; Simard J; Masson JY; Monteiro ANA
    Trends Cancer; 2021 Mar; 7(3):188-197. PubMed ID: 33139182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional variant analyses (FVAs) predict pathogenicity in the BRCA1 DNA double-strand break repair pathway.
    Loke J; Pearlman A; Upadhyay K; Tesfa L; Shao Y; Ostrer H
    Hum Mol Genet; 2015 Jun; 24(11):3030-7. PubMed ID: 25652403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A systematic review of predicted pathogenic PALB2 variants: an analysis of mutational overlap between epithelial cancers.
    Janssen B; Bellis S; Koller T; Tischkowitz M; Liau SS
    J Hum Genet; 2020 Jan; 65(2):199-205. PubMed ID: 31619740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.